2. This is a case of a young male patient who presented with acute myocardial infarction and had a drug-eluting stent placed. He was a
smoker; his left ventricular ejection fraction was 50-55% and he had
Readmore >>
paroxysmal atrial fibrillation. Please comment on the choice of therapy in this case between an antiplatelet agent, warfarin plus antiplatelet agent or
warfarin monotherapy.
2. 이것은 급성 심근 경색이 발생했고 약물 방출 스텐트를 시술한 젊은 남성 환자의 사례입니다. 그는 흡연자였습니다. 좌심실 구혈률은 50-55%이었으며 발작성 심방 세동을 가지고 있었습니다. 이 사례에서 항 혈소판제 또는 와파린과 항 혈소판제 병용 또는 와파린 단독 처치 간의 선택에 대한 의견을 제시해 주십시오.
2. Đây là trường hợp một bệnh nhân nam trẻ có biểu hiện nhồi máu cơ tim cấp tính và đã được đặt một stent tẩy rửa thuốc. Bệnh nhân này có hút thuốc; phân xuất tống máu tâm thất trái của anh là 50-55% và
Readmore >>
anh bị chứng rung nhĩ bộc phát. Hãy đưa ra ý kiến về việc lựa chọn liệu pháp cho trường hợp này giữa việc sử dụng thuốc kháng tiểu cầu, warfarin cộng với việc sử dụng thuốc kháng tiểu cầu hoặc liệu pháp warfarin đơn.
2. Ini adalah kasus seorang pasien laki-laki muda yang memiliki infark miokard akut dan dalam penggunaan stent bersalut obat. Dulunya ia adalah seorang perokok; fraksi ejeksi ventrikular kirinya sebesar
Readmore >>
50-55% dan ia memiliki atrial fibrilasi proksimal. Silakan berkomentar pada pemilihan terapi dalam kasus ini antara agen antiplatelet, warfarin plus agen antiplatelet atau monoterapi warfarin.
The Zena and Michael A. Wiener Cardiovascular
Institute, Icahn School of Medicine at Mount Sinai, USA
Jonathan Halperin is the Robert and Harriet Heibrunn Professor of
Medicine at The Mount Sinai School of Medicine, New York University
and Director of Clinical Cardiology in the Zena and Michael A. Wierner
Cardiovascular Institute at The Mount Sinai Medical Center.
Professor Halperin was awarded an MD from Boston University in
1975. He has previously served in various federal appointments which
included the Cardiovascular and Renal Drugs Advisory Committee of
the U.S. Food and Drug Administration and the National Institutes of
Health where he was in the Data Safety Monitoring board for the clinical trial of aspirin and
simvastatin in pulmonary arterial hypertension and in the clinical trial coordinating centre of
the National Institutes of Health. He was the principal cardiologist who spearheaded the SPAF
(Stroke Prevention in Atrial Fibrillation clinical trials). The trials were conducted in multiple
centres where 3,600 patients and more than 100 investigators were involved. Currently, he is
involved in several clinical trials with the objective of developing more effective drugs for the
prevention of ischemia in a range of cardiovascular disease conditions.
Professor Halperin has authored a wide range of materials including over 100 peer-reviewed
reports, books, chapters, guidelines and position statements, invited articles and reviews, clinical
case reports, and abstracts. His numerous awards and honours include the Champion of Heart
and Stroke, Master of the Society for Vascular Medicine, The Heart of New York Award, The
Heart of New York Presidential Salute, Howard B. Sprague Research Fellowship Award, Samuel
Bronfman Department of Medicine Teaching Excellence, Samuel Bronfman Department of
Medicine Grand Rounds Award, Cardiology Fellows Society of Greater New York, The Simon
Dack Award, The Jacobi Medallion, The Solomon R. Berson Memorial Award, John R. Murray
Award, The University Hospital Chair and the Roland Jackson Memorial Medical Scholarship.
Dr. Raymond Wong is Honorary Clinical Associate Professor and Head of the Division of Haematology at the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is also Consultant in the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong.
Dr. Wong received his medical degree from the Chinese University of Hong Kong and completed his training at Prince of Wales Hospital, Hong Kong in Haematology and Haematological Oncology, Internal Medicine and Clinical Pharmacology and Therapeutics. Dr. Wong undertook his Blood and Marrow Transplantation Fellowship training at the MD Anderson Cancer Center, Texas, USA and gained a Doctor of Medicine at the Chinese University of Hong Kong.
Dr. Wong has broad research interests with a special focus on the biological and therapeutic aspects of leukaemias, autoimmune haematological diseases, stem cell transplantation, bleeding and thrombosis. He served as the Chairman of the Hong Kong Association of Blood Transfusion and Haematology from 2004 to 2005. Dr. Wong is the author or co-author of over 100 peer-reviewed articles, published in international journals such as Blood, Circulation, JAMA and the New England Journal of Medicine.
The Zena and Michael A. Wiener Cardiovascular
Institute, Icahn School of Medicine at Mount Sinai, USA
Dr. Raymond Wong is Honorary Clinical Associate Professor and Head of the Division of Haematology at the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is also Consultant in the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong.